Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

435
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
435
Nursing Clinical Information System01:27

Nursing Clinical Information System

1.3K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

17
Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
17

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inconsistent ethics reporting in individual participant data meta-analyses: a call for updating PRISMA and PRISMA-IPD.

BMC medicine·2026
Same author

Contribution of Countries and International Collaboration in Clinical Pharmacology Research. A Cross-Sectional Bibliometric Study of Six Top Ranked Specialty Society Journals.

Basic & clinical pharmacology & toxicology·2026
Same author

The research integrity risk index for Spanish universities in the European context.

Medicina clinica·2026
Same author

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same author

Would a single centralized ethical review in Europe be feasible for multinational trials in public health emergencies?

European journal of internal medicine·2026
Same author

Real-world evidence terminology should not be abandoned.

Journal of clinical epidemiology·2026

Related Experiment Video

Updated: Feb 14, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Clinical Trials Transparency: Where Are We Today?

Rafael Dal-Ré1

  • 1Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.

Trends in Cancer
|February 8, 2018
PubMed
Summary

Policies enacted since 2005 mandate prospective trial registration and results disclosure to prevent reporting bias. Further transparency measures, including open access to deidentified participant data, were decided upon in 2017, impacting current clinical trial practices.

Keywords:
clinical trialsdisclosure of resultsopen data accessoutcome reporting biaspublication biasregistration of trials

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Feb 14, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Area of Science:

  • Clinical trial transparency
  • Research integrity
  • Data sharing policies

Background:

  • Reporting bias in clinical research is a significant concern.
  • Policies mandating prospective trial registration and results disclosure were implemented starting in 2005.
  • Open access to deidentified participant data is a key component of full trial transparency.

Purpose of the Study:

  • To summarize the evolution of policies aimed at enhancing clinical trial transparency.
  • To highlight the impact of critical decisions made by funders and journals in 2017 on trial transparency requirements.

Main Methods:

  • Review of policies and regulations concerning clinical trial registration and data disclosure.
  • Analysis of decisions made by major funders and journals regarding data sharing.

Main Results:

  • Since 2005, prospective registration and results disclosure have become standard practices.
  • Key decisions in 2017 by funders and journals have further shaped requirements for trial transparency and data access.
  • These evolving policies aim to mitigate reporting bias and promote open science.

Conclusions:

  • The implementation of mandatory registration and results disclosure has progressed significantly.
  • Recent policy shifts emphasize open access to deidentified data, fostering greater research integrity.
  • These ongoing developments are crucial for the future landscape of clinical research transparency.